Overview

Syreon has extensive expertise in health economics, through its experienced staff based both in Europe through the Syreon Research Institute under the direction of Zoltan Kalo MD, PhD (previously a senior health economist at Novartis), and in Vancouver under the direction of Dr. Paul Keown MD, DSc. Both are experts in the field of clinical research and health burden/economic analysis and have published widely in the area. The health economics group is supported by a biostatistical department with significant experience in the analysis of healthcare resource utilization data, as well as data management and project management teams with a full understand of the challenges of collecting both prospective and retrospective resource utilization data.

Economic Analysis

Syreon Research Institute conducts all aspects of health economic analysis, including cost-minimization, cost-effectiveness and cost-utility analysis across a broad range of acute and chronic disease states. Resource utilization is tracked using patient, provider and caregiver sources to detail community and institutional healthcare utilization, and detailed cost vectors are developed for each individual disease indication. Combination of these data enable the detailed calculation of direct and indirect costs of care, of caregiver burden and economic impact, and of economic loss due to illness. Economic modeling using Markov models, probabilistic models, Monte Carlo methods or discrete event simulation enables sophisticated sensitivity and scenario analysis to determine principal influential factors and "what if" scenarios, and estimation of the impact of potential risks or interventions on projected costs and outcomes.

Strategic Pricing

Shorter product development cycles and intense competition is an intense threat to new pharmaceutical products or medical devices that often struggle to achieve their profit and volume objectives. Precise and comprehensive understanding of market needs and opportunities, of pricing options and therapeutic benefit, and in particular of approval and payment options is critical to overcome these barriers. Syreon Research Institute is optimally poised to provide these services. With extensive experience in the pharmaceutical industry, we work with companies to ensure that their products are optimally priced for rapid market uptake and are tightly aligned with patient and provider needs. The economic and pricing expertise of SRI helps companies move from developing products to creating value, and realizing the benefit of this transition.

Health Economics Training

Syreon Research Insitute is rapidly becoming a preferred provider for health economics training to the pharmaceutical and biotechnology industy, by virtue of its clear, comprehensive and expert tutorial method and vast knowledge of the field from both industry and academic perspectives. Dr. Kalo leads a team of highly skilled professional educators combining expertise in health economic analysis, healthcare outcomes, econometric modeling, multivariate statistical analysis, and forecasting.